MWNA
AUPH icon

Marshall Wace North America’s Aurinia Pharmaceuticals AUPH Stock Holding History

Marshall Wace North America’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,200
Closed -$489K – 1200
2020
Q2 		$489K Buy
+30,200
New +$484K ﹤0.01% 927

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Marshall Wace North America's AUPH Position: Q3 2020 in Review

Marshall Wace North America sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2020, closing a stake of 30,200 shares — an estimated $489K sold.

Marshall Wace North America first reported a position in AUPH in Q2 2020 and held it in 1 quarter. The position peaked at $489K in Q2 2020. 145 funds tracked by Wall St. Rank hold AUPH as of Q3 2020.

  • Marshall Wace North America reported no remaining Aurinia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 30,200 Aurinia Pharmaceuticals shares in Q3 2020, an estimated $489K.
  • Marshall Wace North America first reported a position in Aurinia Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Marshall Wace North America's Aurinia Pharmaceuticals position peaked at $489K in Q2 2020.
  • 145 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.